Pro Medicus share price rockets 13% on biggest ever contract win

Pro Medicus shares are leaping higher on Thursday.

| More on:
Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Pro Medicus Ltd (ASX: PME) share price just took a huge leg up in intraday trading.

Shares in the S&P/ASX 200 Index (ASX: XJO) health imaging company closed yesterday at $228.41. They were trading 1.5% higher at 1.30pm AEDT today before rocketing to $258.87, up 13.3%.

After some likely profit-taking, Pro Medicus shares are currently changing hands for $247.25 each, up 8.4%.

As you can see on the chart below, this sees the Pro Medicus stock up an eye-watering 184% in just 12 months.

Created with Highcharts 11.4.3Pro Medicus PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's what's spurring ASX 200 investor interest this afternoon.

Pro Medicus share price soars on $330 million deal

The Pro Medicus share price just took off after the company released an intraday update regarding a major new contract.

Pro Medicus reported that its wholly owned United States subsidiary, Visage Imaging, has signed a 10-year $330 million contract with Trinity Health.

Trinity Health is one of the largest not-for-profit healthcare systems in the US, with 93 hospitals, 107 continuing care locations, and 142 urgent care locations.

The contract will see the ASX 200 healthcare stock's cloud-based Visage 7 Enterprise Imaging Platform implemented throughout Trinity to provide a unified diagnostic imaging platform.

Pro Medicus noted that Trinity Health, like all its recent Visage 7 clients, has opted for a fully cloud-based solution. The company said this is a trend that is "fast becoming the standard in the North American healthcare IT market".

Management said that planning for the rollout would start immediately. The rollout will be based on Visage's proven cloud-based implementation process. Multi-phased go-lives are targeted to begin in early Q3 of the 2025 calendar year.

Commenting on the contract sending the Pro Medicus share price soaring, CEO Sam Hupert said:

Trinity Health is our largest customer to date and the first with a national footprint. Our initiative with Trinity Health is noteworthy for its scope and scale which will see the Visage 7 platform used by over 650 Radiologists and thousands of clinicians who will benefit from the proven differentiation of Visage 7…

Our pipeline remains strong and spans all market segments. As has been the case with many of our recent contracts, this deal is for our 'full-stack' comprising all three core Visage products, a trend we see continuing.

If the Pro Medicus share price manages to hold onto the gains at close, as looks likely to me, this will mark another new all-time closing higher for the ASX 200 health imaging company.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »